MX2019007255A - Metodos y composiciones para prevenir o minimizar la transicion epitelio mesenquima. - Google Patents

Metodos y composiciones para prevenir o minimizar la transicion epitelio mesenquima.

Info

Publication number
MX2019007255A
MX2019007255A MX2019007255A MX2019007255A MX2019007255A MX 2019007255 A MX2019007255 A MX 2019007255A MX 2019007255 A MX2019007255 A MX 2019007255A MX 2019007255 A MX2019007255 A MX 2019007255A MX 2019007255 A MX2019007255 A MX 2019007255A
Authority
MX
Mexico
Prior art keywords
emt
compositions
pro
fatty acid
agent
Prior art date
Application number
MX2019007255A
Other languages
English (en)
Inventor
Gagnon Lyne
Laurin Pierre
Original Assignee
Prometic Pharma Smt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Pharma Smt Ltd filed Critical Prometic Pharma Smt Ltd
Publication of MX2019007255A publication Critical patent/MX2019007255A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen composiciones, lo que incluye composiciones de albúmina, que inhiben o reducen la transición epitelio mesénquima (EMT). En modalidades, tales composiciones comprenden albúmina y ya sea i) ningún agente pro-EMT o una baja concentración de agente pro-EMT; ii) un contenido de agente pro-EMT y agente anti-EMT en una relación de agente pro-EMT:agente anti-EMT que es de 7:3 a 0:10, o iii) ambos. El agente pro-EMT es ácido octanoico, sal de octanoato o una combinación de estos. El agente anti-EMT es un ácido graso C9-CM, una sal de ácido graso C9-CM, un monoglicérido de ácido graso C9-CM, un diglicérido de ácido graso C9-CM, un triglicérido de ácido graso C9-CM o una combinación de estos. El uso de tales composiciones de albúmina para diversas aplicaciones terapéuticas basadas en albúmina y más particularmente, para el tratamiento de enfermedades o afecciones en las que se debe prevenir o minimizar la EMT. Estas composiciones de albúmina pueden usarse ventajosamente en combinación con ingredientes activos conocidos. Además, se describen composiciones de un agente anti-EMT para uso en el tratamiento de diversas indicaciones terapéuticas y más particularmente, para el tratamiento de enfermedades o afecciones en las que se debe prevenir o minimizar la EMT.
MX2019007255A 2016-12-21 2017-12-20 Metodos y composiciones para prevenir o minimizar la transicion epitelio mesenquima. MX2019007255A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437123P 2016-12-21 2016-12-21
US201762462530P 2017-02-23 2017-02-23
PCT/IB2017/001593 WO2018115953A1 (en) 2016-12-21 2017-12-20 Methods and compositions for preventing or minimizing epithelial-mesenchymal transition

Publications (1)

Publication Number Publication Date
MX2019007255A true MX2019007255A (es) 2019-11-05

Family

ID=61024798

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019007255A MX2019007255A (es) 2016-12-21 2017-12-20 Metodos y composiciones para prevenir o minimizar la transicion epitelio mesenquima.
MX2021014561A MX2021014561A (es) 2016-12-21 2019-06-18 Uso de una composicion de albumina con o sin agentes pro-emt y anti-emt (agentes para prevenir o minimizar la transicion epitelio mesenquima emt), para el tratamiento de enfermedades o afecciones de hemorragias, quemaduras, disfuncion hepatica, cancer, etc.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021014561A MX2021014561A (es) 2016-12-21 2019-06-18 Uso de una composicion de albumina con o sin agentes pro-emt y anti-emt (agentes para prevenir o minimizar la transicion epitelio mesenquima emt), para el tratamiento de enfermedades o afecciones de hemorragias, quemaduras, disfuncion hepatica, cancer, etc.

Country Status (15)

Country Link
US (2) US20210128694A1 (es)
EP (1) EP3558289A1 (es)
JP (2) JP2020502203A (es)
KR (1) KR20190102011A (es)
CN (1) CN110290786A (es)
AU (1) AU2017381449B2 (es)
BR (1) BR112019012538A2 (es)
CA (1) CA3047523A1 (es)
IL (1) IL267208A (es)
MX (2) MX2019007255A (es)
PH (1) PH12019501372A1 (es)
RU (1) RU2764630C2 (es)
TW (1) TW201825110A (es)
WO (1) WO2018115953A1 (es)
ZA (1) ZA201904558B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11076916B2 (en) 2015-12-23 2021-08-03 Rhode Island Hospital Thermal accelerant compositions and methods of use
CN112516291B (zh) * 2019-09-17 2023-07-14 通化安睿特生物制药股份有限公司 含人白蛋白的制剂及其制备方法
US11484551B2 (en) 2019-11-20 2022-11-01 Alkahest, Inc. Method of treating liver failure with plasma fraction IV-4
CA3156906A1 (en) * 2019-11-20 2021-05-27 Alkahest, Inc. Blood plasma fractions for use in liver regeneration
AU2022279993A1 (en) * 2021-05-24 2024-01-18 Theromics, Inc. Devices, methods, and compositions for thermal acceleration and drug delivery
CN114712521B (zh) * 2022-03-22 2024-06-21 郑州大学 一种靶向cd44受体的药物及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01211530A (ja) * 1988-02-16 1989-08-24 Pola Chem Ind Inc 抗腫瘍剤
JPH0671432B2 (ja) * 1991-03-20 1994-09-14 株式会社ミドリ十字 ヒト血清アルブミンの製造方法
US5780594A (en) 1993-03-01 1998-07-14 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Biologically active protein fragments containing specific binding regions of serum albumin or related proteins
JPH09208486A (ja) * 1996-02-07 1997-08-12 Yasuo Umetsu 血清アルブミンの部分構造を有する細胞障害物質
US5948609A (en) 1997-12-03 1999-09-07 Carter; Daniel C. Oxygen-transporting albumin-based blood replacement composition and blood volume expander
US6787636B1 (en) 2000-07-14 2004-09-07 New Century Pharmaceuticals, Inc. Modified serum albumin with reduced affinity for nickel and copper
US7252799B2 (en) * 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
JP4259324B2 (ja) 2002-02-28 2009-04-30 ニプロ株式会社 安定化されたアルブミン製剤
PT1853250E (pt) * 2005-02-18 2012-02-03 Abraxis Bioscience Llc Combinações e modos de administração de agentes terapêuticos e terapia de combinação
EP1966239A1 (de) * 2005-12-22 2008-09-10 CSL Behring GmbH Oktanoatreduziertes human albumin
BRPI0818310A8 (pt) * 2007-11-02 2017-12-26 Prometic Biosciences Inc Glicerídeos e ácidos graxos de cadeia média como agentes nefroprotetores
US7998688B2 (en) 2008-03-07 2011-08-16 OSI Pharmaceuticals, LLC Inhibition of EMT induction in tumor cells by anti-cancer agents
RU2586493C2 (ru) * 2009-03-13 2016-06-10 Берген Текнологиоверфоринг Ас Способ применения axl в качестве маркера эпителиально-мезенхимального перехода
CA2776241A1 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
CN101745103B (zh) * 2010-01-19 2011-09-28 广东卫伦生物制药有限公司 可常温保存的白蛋白制剂
WO2011124718A1 (en) 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
GB2491006A (en) 2011-05-05 2012-11-21 Novozymes Biopharma Uk Ltd Albumin variants
CA2838964C (en) * 2011-07-05 2021-07-13 Novozymes Biopharma Dk A/S Albumin formulation and use
CA2866590A1 (en) * 2012-03-07 2013-09-12 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
US20150165000A1 (en) 2012-12-18 2015-06-18 Ewha University - Industry Collaboration Foundation Composition for thermostabilization of human serum albumin and method of preparing thermally stabilized human serum albumin using the same
CN104434808A (zh) 2014-07-03 2015-03-25 石药集团中奇制药技术（石家庄）有限公司 一种治疗性纳米粒子及其制备方法

Also Published As

Publication number Publication date
IL267208A (en) 2019-08-29
AU2017381449B2 (en) 2021-10-28
RU2764630C2 (ru) 2022-01-19
JP2020502203A (ja) 2020-01-23
US20230346893A1 (en) 2023-11-02
TW201825110A (zh) 2018-07-16
CN110290786A (zh) 2019-09-27
WO2018115953A1 (en) 2018-06-28
US20210128694A1 (en) 2021-05-06
MX2021014561A (es) 2022-01-11
CA3047523A1 (en) 2018-06-28
PH12019501372A1 (en) 2020-01-20
ZA201904558B (en) 2020-12-23
BR112019012538A2 (pt) 2019-11-12
JP2023017017A (ja) 2023-02-02
AU2017381449A1 (en) 2019-07-25
KR20190102011A (ko) 2019-09-02
EP3558289A1 (en) 2019-10-30
RU2019122735A3 (es) 2021-05-31
RU2019122735A (ru) 2021-01-22

Similar Documents

Publication Publication Date Title
MX2021014561A (es) Uso de una composicion de albumina con o sin agentes pro-emt y anti-emt (agentes para prevenir o minimizar la transicion epitelio mesenquima emt), para el tratamiento de enfermedades o afecciones de hemorragias, quemaduras, disfuncion hepatica, cancer, etc.
HRP20211706T1 (hr) Nukleazom posredovana regulacija ekspresije gena
PH12017502181A1 (en) Nutritional compositions containing an elevated level of inositol and uses thereof
EA201991467A1 (ru) Состав смеси, содержащий силикат и микробные и/или растительные клетки и полиненасыщенную жирную кислоту, имеющую по меньшей мере 20 атомов углерода (lc-pufa)
PH12016502100A1 (en) Liquid formulation comprising gm-csf neutralizing compound
ZA201504284B (en) Solution for preserving vascular conduits
BRPI0520167A2 (pt) formulaÇÕes aprimoradas de fenofibrato contendo mentol ou uma mistura de peg/poloxÂmero
AU2017356887A8 (en) sGC stimulators
ES2721761T3 (es) Composición de baño de espuma
JP2021500092A5 (es)
MY193776A (en) Modified cytotoxins and their therapeutics use
BR112017027909A2 (pt) composição, e, uso de uma composição
EA201291335A1 (ru) Фармацевтические композиции для местного применения
MX2021014371A (es) Composiciones que comprenden acidos grasos cetilados y uso de las mismas en el tratamiento de la artritis y de afecciones inflamatorias de las articulaciones.
BR112018072235A2 (pt) formulações e métodos para tratar organismos fotossintéticos e aumentar as qualidades e quantidades das produções com formulações de compósitos de glicano
BR112015004632A2 (pt) gordura de cobertura de confeitaria com gordura de baixa saturação
Melo et al. Antiperoxidative properties of oil mixes of high ratio Omega-9: Omega-6 and low ratio Omega-6: Omega-3 after molar extraction in rats
BR112018006343A2 (pt) composição de gordura de safa reduzidos, e, emulsão aerada
EA202290122A1 (ru) Фармацевтические композиции в форме геля, содержащие ксилоглюкан и спирты, для регулируемого высвобождения активных ингредиентов
NZ767092A (en) Flower thinning composition and flower thinning method using same
EA202090728A1 (ru) Применение нор-урсодезоксихолевой кислоты для снижения печеночного жира
WO2017025896A3 (en) Compositions and methods for treating wounds
CL2021000520A1 (es) Una composición que contiene hierro y uso de la misma
WO2016126026A3 (ko) 당뇨병 치료 조성물 및 이의 용도
PL404379A1 (pl) Maść